A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- Citation:
- Oncologist vol 15 (12) 1310-1319
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 612
- Children:
- None
- Pharmas:
- Grants:
- U10 CA047577, U10 CA032291, CA33601, CA77597, CA11789, U10 CA077658, CA77406, CA47577, CA35113, CA32291, U10 CA086726, CA41287, U10 CA035279, U10 CA045808, U10 CA031946, CA77651, U10 CA033601, U10 CA045389, CA45389, U10 CA077597, CA45808, CA35279, U10 CA045418, CA86726, U10 CA077440, CA77440, U10 CA041287, U10 CA035113, U10 CA077651, CA04326, CA08025, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31946
- Corr. Author:
- Authors:
- Eileen M. O'Reilly Donna Niedzwiecki Margaret Hall Donna Hollis Tanios Bekaii-Saab Timothy Pluard Kathe Douglas Ghassan K. Abou-Alfa Hedy L. Kindler Richard L. Schilsky Richard M. Goldberg
- Networks:
- Study
- CALGB-80603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Sunitinib, Phase II, Refractory, Pancreas adenocarcinoma, CALGB 80603